Effect of Atorvastatin Treatment on Vascular Aterogenic Factors (Lipid Profiles and VCAM-1) in Patient Diabetes with Dyslipidemia

Asri Wido Mukti

Abstract


To analyze effectiveness of atorvastatin 20mg on lipid profiles and adhesion molecule VCAM-1 in patient with diabetes dyslipidemia. An observational prospective cohort study was conducted from November 2016 to March 2017. Patients who fulfilled the inclusion criteria were taken twice for their lipid profiles and VCAM-1 measurements (before initiation of study and after 6 weeks treatment of atorvastatin 20mg). There were 13 patients who met the inclusion criteria. The results of 13 patients showed that after 6 weeks of atorvastatin therapy, there was a 28% decrease in total cholesterol (t0=223.77±49.69, t1=160.92±24.69), 39% LDL decrease (t0=152.59±44.25, t1 =93±21.44), a decrease in TG 38.6% (t0=200.85±101.53, t1=123.30±62.77) and a statistically significant decrease in VCAM-1 7.47% (t0=729.59±208.06, t1=675.06±182.88). The results of the correlation test between total cholesterol and VCAM-1 (p=0.185, r=0.268), LDL and VCAM-1 (p=0.127, r=0.307), TG and VCAM-1 (p=0.198, r=0.261) showed no correlation. Based on the results of the study, it can be concluded that atorvastatin therapy can provide improvements in atherogenic factors such as decreased lipid profile  and VCAM-1, and there was no correlation between lipid profile and VCAM-1 in type 2 DM patients with dyslipidemia.

 


Keywords


Atorvastatin, Adhesion molecules, Diabetes mellitus, , dyslipidemia, VCAM-1.

Full Text:

PDF

References


Chehade et al., 2013. Dyslipidemia in Type 2 Diabetes : Prevalence, Pathophysiology, and Management. Drugs 73:327-339.

Fasching P, Veitl M, Rohac M, et al., 1996. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism ;81:4313–17.

George, Sarah Jane; Lyon, Cressida, 2010. Pathogenesis of Atherosclerosis, In : Atherosclerosis Molecular and Cellular Mechanisms. Weinheim : WILEY-VCH Verlag GmbH & Co. KGaA, pp-3-14.

Hegele et al., 2013. Dyslipidemia. Canadian Journal of Diabetes 37 : S110eS116.

Hogue, Jean-Charles; Benoît Lamarche; André J. Tremblay, et al., 2008. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism Clinical and Experimental 57 (2008) 380 – 386.

Hubel, Carl A; Fiona Lyall; Lisa Weissfeld; Robin E. Gandley; and James M. Roberts, 1998. Small Low-Density Lipoproteins and Vascular Cell Adhesion Molecule-1 Are Increased in Association With Hyperlipidemia in Preeclampsia. Metabolism,Vol47, No 10(October),1998:pp 1281-1288.

Lastra, Guido; Sofia Syed, L; Romayne Kurukulasuriya et al., 2014. Type 2 diabetes mellitus and hypertension: An update. Endocrinology and Metabolism Clinics of North America 2014 March ; 43(1): 103–122.

Malloy,Mary J. & John P. Kane, 2012. Agents Used in Hyperlipidemia In : Basic & Clinical Pharmacology 10th edition. USA : McGraw-Hill. pp. 625

Mihardja, Laurentia; Uken Soetrisno; and Sidartawan Soegondo, 2014. Prevalence and clinical profile of diabetes mellitus in productive aged urban Indonesians. Journal of Diabetes Investigation 2014; 5: 507–512.

NCEP-expert-panel, third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation 106 (2002) 3143–3421Ohtawa, M., Masuda, N., Akasaka, I., et al., Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells. British Journal of Clinical Pharmacology, 1999, 47:383-389.

Triplitt et al., 2014. Diabetes Mellitus, In : Pharmacotherapy A Pathophysiologic Approach 9th edition . USA : McGraw Hill. pp 643-647

Wang, Huang; Huo, Yuqing, 2010. Adhesion Molecules and Atherosclerosis, In : Atherosclerosis Molecular and Cellular Mechanisms. Weinheim : WILEY-VCH Verlag GmbH & Co. KGaA, pp 43-55

Wibisono et al., 2012. Profil Albuminuria dan Kadar sVCAM-1 Pada Penderita Diabetes Melitus Tipe 2. Jurnal Penyakit Dalam Vol 13 Nomor 1 Januari. Hal 28-35.




DOI: http://dx.doi.org/10.14499/indonesianjpharm30iss2pp128-132

Refbacks

  • There are currently no refbacks.




Copyright (c) 2019 Indonesian Journal of Pharmacy

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:

                                    
 
web
analytics View My Stats